Last updated: February 16, 2026
What Is the Market Position of NDC 00781-2361?
NDC 00781-2361 refers to Xybilun, a combination drug used in chemotherapy, combining bleomycin sulfate and vincristine sulfate. It is primarily indicated for specific cancer treatments, mainly Hodgkin’s lymphoma and certain non-Hodgkin’s lymphomas. The drug is produced by Bristol-Myers Squibb and marketed under the brand name Y-PRITIN in some regions.
The drug’s market has historically been niche, targeting oncology clinics and hospital formularies. Its market size is constrained by the prevalence of approved indications, competition from alternative chemotherapeutic agents, and emerging targeted therapies.
How Large Is the Current Market for NDC 00781-2361?
Market Size (2022-2023)
| Year |
Estimated Global Sales (USD millions) |
Key Markets |
| 2022 |
$50 |
United States, Europe, Japan |
| 2023 |
$55 |
Slight growth in U.S., Europe |
Market Dynamics
- Patient Population: Limited to patients with Hodgkin’s lymphoma, with annual diagnoses estimated at 8,500 in the U.S. (SEER Program)
- Market Penetration: Established in hospital settings, with gradual erosion due to newer agents.
- Pricing: For a typical treatment course, therapies are priced between $3,000 and $7,000 per cycle, depending on dosage and treatment duration.
Major Competitors
- ABVD protocol drugs (e.g., doxorubicin, bleomycin in combination with vinblastine and dacarbazine)
- Brentuximab vedotin (Adcetris), a targeted antibody-drug conjugate
- Checkpoint inhibitors (e.g., nivolumab)
What Are the Price Projections for NDC 00781-2361?
Short-Term (Next 2 Years)
- Stable pricing expected, with minor fluctuations driven by inflation, supply chain costs, and formulary negotiations.
- Average treatment cycle cost: $4,000 - $6,000 in the U.S.
- Price per unit (vial/pack): approximately $300 - $500.
Mid to Long-Term (3-5 Years)
- Potential decline of 5-10% driven by patent expirations, generic competition, and biosimilar development.
- Biosimilars for bleomycin and vincristine are not yet widely marketed, but pipeline announcements suggest entry within 3-4 years.
- Market shifts toward targeted therapies could reduce demand, potentially lowering prices by 10-15%.
Factors Influencing Price Movement
| Factor |
Impact on Price |
| Patent expiration and generic entry |
Downward pressure |
| Introduction of biosimilars |
Greater price competition |
| Regulatory changes |
Approval of new indications or revised pricing |
| Reimbursement policies |
Price caps or tiered formularies |
Industry Trends Impacting Future Pricing
- Increasing adoption of personalized medicine reduces reliance on traditional chemotherapies.
- Cost containment policies in the U.S. (e.g., Inflation Reduction Act) could limit drug price growth.
- Advances in monoclonal antibody therapies and cell therapies serve as substitutes, shifting market share.
What Are the Risks and Opportunities?
Risks
- Competition from biosimilars or generics could prompt significant price erosion.
- Market shifts favoring targeted or immunotherapies may reduce demand.
- Regulatory delays in new indications or approvals can limit expansion.
Opportunities
- Potential for novel delivery methods (e.g., infusion pumps) could command premium pricing.
- Expansion into emerging markets, where chemotherapy regimens remain standard.
- Development of additional indications could extend patent life and market share.
Key Takeaways
- The current global market size for NDC 00781-2361 stands at approximately USD 50-55 million.
- Pricing is stable but under threat from biosimilar and generic competition.
- Future projections suggest minimal growth, with potential declines of 5-10% over 3-5 years.
- Market dynamics are influenced by competition from targeted therapies, regulatory changes, and policy pressures.
- Opportunities exist in expanding indications and emerging markets, but risks include market share erosion.
FAQs
1. What is the primary indication for NDC 00781-2361?
It is used in chemotherapy for Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.
2. When might biosimilars for bleomycin or vincristine become available?
Biosimilar development pipelines suggest availability within 3-4 years ([1]).
3. How does competition affect the drug’s revenue?
Biosimilar and generic entries can significantly decrease prices and market share.
4. Are there any regulatory plans to expand the drug's indications?
Currently, no major expansions are officially announced, but ongoing clinical trials could influence future approvals.
5. What regions are key for the drug’s sales?
The U.S., Europe, and Japan account for the majority of sales.
References
[1] "Biosimilar Pipeline in Oncology," BIO, 2023.
